🇺🇸 FDA
Patent

US 8193181

Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine

granted A61KA61K31/538A61K45/06

Quick answer

US patent 8193181 (Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine) held by Rigel Pharmaceuticals, Inc. expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/538, A61K45/06, A61P, A61P1/00